electroCore Third Quarter 2026 Earnings Call - ELECTROCORE INC

Explicit Guidance:

• FY2026 Revenue: Revised guidance range of $39 million to $42 million (previously >30% YoY growth); implies the acceleration expected in H2 2026 will occur in 2027.
• FY2027 Revenue: Preliminary guidance for 30% to 40% year-over-year growth in full-year 2027.
• Adjusted EBITDA: Expectation to achieve the first fiscal quarter of positive adjusted EBITDA by the end of 2027.
• Capital Structure: Plan to reach positive EBITDA without entering into a new dilutive equity capital financing transaction, supported by existing cash ($7.5M as of Sept 30, 2026) and financing resources; actively evaluating refinancing options for the existing term loan to extend principal repayment timing.
• Margins: Anticipated gross margins in the upper 80s on a streamlined cost base.

Business-Segment Outlook:

• VA Channel (Primary Driver):
  • Coverage Expansion: Expect full staffing of VA accounts beginning October 2026; goal of 14 new patients per month per account (combining GammaCore and Quell).
  • Salesforce Efficiency: New independent representatives added since June average $210,000/month in VA revenue (up 30% from $160k baseline); trending toward $300,000/month by October. New account ramp-up time reduced from 6–7 months to ~2 months.
  • Refill Rates: Current national refill rate is 42%; goal to increase to >70% via new patient training initiatives, with improvements expected to materialize in Q4 2026 and early 2027.
  • QWEL Growth: October 2026 was a record month for QWEL (passing 1,000 VA patients in 2026 alone); revenue trends align with 30–40% growth in 2027.
  • Channel Shift: Lovell Government Services accounts for ~91% of VA orders (up from 57% in June); expected to reduce transaction fees by 3% and free internal resources for new markets.
• Direct-to-Consumer (TrueVega): Not chasing "empty calorie" revenue; revenue growth expected to be slower year-over-year compared to 2025/2026 to prioritize Return on Advertising Spend (ROAS) and profitability over top-line volume.
• Commercial Expansion:
  • Kaiser: Engagement in coverage discussions for markets outside California; internal evaluation results in California encouraged.
  • DoD/TRICARE: Identified pilot areas for federal workers' compensation; engaged in contract discussions for VA Women's Health and First Responders.
  • Oncology: Evaluating specialized sales approaches for chemotherapy-induced peripheral neuropathy (CIPN) targeting oncologists and nurse practitioners, though current sales force is expected to handle a significant number of opportunity accounts initially.

Market and Competitive Outlook:

• CIPN Indication (QWEL): If 510K clearance is obtained, Quell could become the first non-drug option specifically indicated for CIPN, addressing an unmet need with no current medical device or pharmaceutical alternative.
• Market Size Estimates: US total addressable market for CIPN estimated at $600–700 million; VA specific market estimated at $15–20 million.
• Competitive Landscape: TrueVega faces increased competition in branded search terms (60% increase in competitors), driving up cost per click by ~42%, necessitating a shift to more efficient acquisition strategies.
• Other Applications: Exploring opportunities for enhanced performance in high-stress roles (Air Traffic Controllers, Police, SWAT) based on Air Force Research Lab data; targeting first responders and federal workers' compensation markets.

Macro / Industry Outlook:

• Regulatory Timeline: FDA 510K review for CIPN typically targets 90 review days; management expects the first communication/response in the back half of Q1 2027. Actual sales revenue generation from this indication would likely not begin until H2 2027.
• Regulatory Risks: A previously issued Form 483 regarding a 2017 OTC product is not expected to delay the current CIPN 510K submission.
• Reimbursement Dynamics: Acknowledges that expanding beyond the VA (commercial space) requires complex reimbursement coverage negotiations, which may extend timelines for non-federal market penetration.

Strategic Initiatives:

• FDA Submission: 510K pre-market notification for Quell for CIPN filed October 27, 2026 (following the recall and resubmission of a previous de novo application per FDA advice).
• Salesforce Restructuring: Split VP of Sales into East and West Area VPs; added two new Regional Sales Directors in October with a third pending; adopted a "smaller territory" model to increase accountability and coaching.
• Operational Efficiencies: R&D expenses decreased to $400k in Q3 (down from $700k prior year); SG&A expenses down to $9.7M (down from $10.1M in Q2); inventory build-up to $4M to support forecasted growth.
• OTC Product Delay: Planned launch of Quell OTC (Quell 2.0) delayed due to Form 483 commentary and a strategic decision to prioritize profitable revenue streams for 2027 profitability goals.

Risks and Headwinds to Outlook:

• Timing Shifts: Revenue acceleration expected in H2 2026 has been pushed to 2027; FY2026 growth guidance reflects this delay.
• FDA Uncertainty: While optimistic, final clearance for CIPN is subject to FDA review timelines and potential information requests (which stop the clock).
• Sales Force Performance: Confidence relies on new reps maintaining productivity levels and the speed of account ramp-up; saturation risks are considered low but market-dependent.
• Financing: Refinancing of the existing term loan is currently under evaluation with no guarantees; failure to secure favorable terms could impact cash runway.
• Competition: Rising competitive intensity in DTC search advertising increases customer acquisition costs.

Management Tone on the Future:

• Confidence Level: High confidence ("conviction has not wavered") driven by "early proof" that the new sales model works, despite the timing shift.
• Strategic Shift: Explicitly moving away from "short-term gains" and "empty calorie revenue" toward "durable, repeatable, and profitable" growth.
• Narrative: Framing the revised 2026 guidance not as a negative, but as a "change in timing, not direction," with the belief that 2027 growth will be more sustainable.
• Execution Focus: Emphasis that the "next 12 months are about execution" and turning early KPI indicators into sustained financial results.

Miscellaneous:

• Key Personnel: Dr. Thomas Errico (Chairman), Joshua Lev (Co-CEO/CFO), and Mike Fox (Co-CEO/COO) leading the transformation.
• Cash Position: $7.5M in cash, cash equivalents, and marketable securities as of Sept 30, 2026 (down from $10M in June 2026 due to inventory build).
• M&A History: Gross sales growth driven partly by the acquisition of Quell Fibromyalgia products from Neurometrics, Inc. in May 2025.